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Abstract
Objectives To assess the accuracy of fetal RHD genotyping using
cell-free fetal DNA in maternal plasma at different gestational ages.
Design A prospective multicentre cohort study.
Setting Seven maternity units in England.
Participants RhD negative pregnant women who booked for antenatal
care before 24 weeks’ gestation.
InterventionsWomen who gave consent for fetal RHD genotyping had
blood taken at the time of booking for antenatal care and, when possible,
at other routine visits such as for Down’s syndrome screening between
11 and 21 weeks’ gestation, at the anomaly scan at 18-21 weeks, and
in the third trimester when blood was taken for the routine antibody
check. The results of cord blood analysis, done routinely in RhD negative
pregnancies, were also obtained to confirm the fetal RHD genotyping.
Main outcome measures The accuracy of fetal RHD genotyping
compared with RhD status predicted by cord blood serology.
ResultsUp to four analyses per woman were performed in 2288 women,
generating 4913 assessable fetal results. Sensitivity for detection of fetal
RHD positivity was 96.85% (94.95% to 98.05%), 99.83% (99.06% to
99.97%), 99.67% (98.17% to 99.94%), 99.82% (98.96% to 99.97%),
and 100% (99.59% to 100%) at <11, 11-13, 14-17, 18-23, and >23
completed weeks’ gestation, respectively. Before 11 weeks’ gestation
16/865 (1.85%) babies tested were falsely predicted as RHD negative.
Conclusions Mass throughput fetal RHD genotyping is sufficiently
accurate for the prediction of RhD type if it is performed from 11 weeks’
gestation. Testing before this time could result in a small but significant
number of babies being incorrectly classified as RHD negative. These
mothers would not receive anti-RhD immunoglobulin, and there would
be a risk of haemolytic disease of the newborn in subsequent
pregnancies.
Introduction
Haemolytic disease of the fetus and newborn is caused by
maternal IgG antibodies to red cell surface antigens crossing
the placenta and facilitating the immune destruction of fetal red
cells or erythroid progenitors. The most commonly implicated
antigen is the RhD (RH1) antigen of the rhesus system. Postnatal
prophylaxis with anti-RhD immunoglobulin substantially
reduces the alloimmunisation of RhD negative women and the
prevalence of haemolytic disease of the fetus and newborn.1
Subsequent introduction of routine antenatal prophylaxis with
anti-RhD immunoglobulin in the third trimester for all RhD
negative pregnant women is now standard in many countries.2
In a predominantly white population, however, about 38% of
these women would be carrying an RhD negative fetus and thus
receive anti-RhD immunoglobulin, a pooled human plasma
product, unnecessarily.3 Prophylaxis after delivery is offered
only to RhD negative women who have given birth to an RhD
positive baby.
Since the identification of cell-free fetal DNA in the blood of
pregnant women,4 several laboratories have provided a fetal
RHD genotyping service for RhD negative women with a
measureable concentration of anti-RhD antibody.5 Cell-free
fetal DNA in maternal plasma is tested for the presence or
absence of the RHD gene, and results are used to direct
management of the pregnancy.5
Consequent to the success of fetal RHD genotyping in high risk
women, the National Institute for Health and Care Excellence
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has “endorsed studies into the feasibility of mass testing
antenatally for fetal blood group by analysis of cell-free fetal
DNA inmaternal plasma.”2 If fetal RHD testing proved accurate
enough, there would be no need to test cord red cells
serologically for RhD status.
High risk alloimmunised women are tested with a labour
intensive low throughput method, which is unsuitable for mass
screening.6 Two studies have used high throughput methods,
including robotic isolation of plasma DNA and real time
quantitative polymerase chain reaction (PCR) technology, to
routinely determine fetal RHD status at 30 weeks in the
Netherlands 7 and at 28 weeks in the United Kingdom,8 with
99.4% and 95.7% diagnostic accuracy when compared with
cord blood serology. If the results of the UK trials had been
applied as a guide to treatment, only 2% of the women would
have received anti-RhD immunoglobulin unnecessarily,
compared with 38% in the absence of genotyping. Similar
accuracy was achieved in validation studies in Germany9 and
France,10 but the latter involved re-testing all negative results,
which would be uneconomical.10
In Denmark and the Netherlands routine fetal RHD genotyping
has recently been introduced as a national service at 26 and 28
weeks, respectively.11 12 As routine anti-RhD prophylaxis is
recommended from 28 weeks, and anti-RhD immunoglobulin
is administered earlier in pregnancy after any potential
sensitising event, implementation of fetal RHD testing earlier
in pregnancy would maximise potential benefits and cost
reduction. As concentrations of cell-free fetal DNA in maternal
blood increase throughout the pregnancy,13 it cannot be assumed
that tests will be as accurate early in pregnancy as they are at
26-28 weeks’ gestation.
We estimated the diagnostic accuracy and costs of fetal RHD
genotyping in RhD negative pregnant women from the time of
booking until 28 weeks’ gestation to determine the optimal
gestation for implementation into routine clinical practice. The
economic impact of testing will be reported separately.
Methods
Population
Women booking for antenatal care in 2009-12 at sevenmaternity
units in England were prospectively asked for verbal consent
to donate an additional 4 mL of blood at the time of their
booking appointment. These appointments were in hospital
antenatal clinics or the community according to local clinical
practice. Local midwives got verbal consent fromwomenwhen
possible. Blood samples from RhD positive women were
discarded, and those from RhD negative women were sent to
the International Blood Group Reference Laboratory for fetal
RHD genotyping, to arrive within 48 hours of blood being
drawn. When possible, we also obtained consent to collect
additional blood samples opportunistically for fetal RHD
genotyping from RhD negative women with singleton
pregnancies when they attended for Down’s syndrome screening
(at 11-20 weeks) and the routine anomaly scan (at 18-23 weeks)
(fig 1⇓). While it is recommended that all women book for
antenatal care early in pregnancy, before the offer of the
combined screening test for Down’s syndrome, which is
performed at 11-13 weeks and 6 days, not all do. For the purpose
of our study we included only women who booked before 24
weeks’ gestation, agreed to participate in the study, and donated
at least one blood sample before 24 weeks’ gestation. Those
who booked before 11 weeks might have donated up to four
blood samples: at booking; at the time of screening for Down’s
syndrome (either the combined test at 11-13 weeks and 6 days
or second trimester screening at 14-20 weeks); at the routine
anomaly scan, which, although recommended at 18-21 weeks
and 6 days, can be performed as late as 24 weeks in some
circumstances; and after 25 weeks at the routine third trimester
antenatal visit, when blood is taken to check haemoglobin and
antibody concentrations.
Written informed consent was obtained before or at the routine
third trimester visit (around 28 weeks), when the women were
given the result of molecular testing and an additional blood
sample was requested to confirm fetal RHD status. When third
trimester testing confirmed that the fetus was RHD negative,
women were allowed to opt out of receiving anti-RhD
immunoglobulin if they requested to do so as the reliability of
testing at this gestation is proved.8 11 All women predicted to be
carrying an RhD positive baby, or when the fetal genotyping
result was inconclusive, were offered anti-RhD immunoglobulin
according to local clinical practice. All women experiencing a
sensitising event before 28 weeks’ gestation were also offered
anti-RhD immunoglobulin according to local clinical practice.
Fetal genotyping from maternal blood
On receipt of blood samples, plasma was prepared and analysed
prospectively by using assay techniques and criteria for the
determination of fetal RHD status as described previously.8
Serological RHD testing on cord bloods
RhD typing on cord blood samples was performed with
serological methods routinely used by participating units. Results
were ascertained by the research midwives and compared with
the genotype predicted.
Data analysis
We included results obtained fromRhD negative women before
25 weeks with a singleton pregnancy who gave written consent
for fetalRHD genotyping and in whom a cord blood RhD group
was subsequently obtained. Genotyping results were interpreted
as RHD positive, RHD negative, or inconclusive. Sensitivity
for the detection of RHD positivity was calculated on the basis
that inconclusive results were treated as RHD positive. We used
generalised linear models with random intercept to quantify
trends in sensitivity and specificity with gestational age while
taking into account repeat measures from the same woman. All
estimates are presented with 95% confidence intervals.We used
R (version 2.14.0) library glmmML to fit the models with 5000
bootstrap samples for estimation of standard errors.
Results
Women were recruited from 2009 to 2012. Of the samples
received at the International BloodGroup Reference Laboratory,
172 were excluded from the analysis because of extreme
haemolysis (average transit time 8.5 days), and a further 22
were not analysed because they did not contain sufficient blood.
Samples from 30 women were excluded because of multiple
pregnancy, 185 because no cord blood result was subsequently
obtained, and 372 because of lack of written consent. We
included results of fetal RHD genotyping from 2288 women in
the final analysis. We had 4913 fetal genotype results with up
to four analyses per woman; 436 had only one measurement,
1132 had two, 667 had three, and 53 had four. Most women
were white (78%), 5.8%were Asian, 3.9%were black or mixed
race, and 12.3%were unknown. Gestational age at measurement
varied from five to 35 weeks (mean 18.67, median 19).
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Genotyping results were inconclusive for 393/4913 (8%, 95%
confidence interval 7.27% to 8.79%) of the samples (table 1⇓).
Analysis of cord blood showed that 2023 samples were from
RhD negative babies, of which 18 had been falsely predicted
antenatally to be genotypically RHD positive and 85 had been
inconclusive; 2890 were RhD positive, of which 308 had been
inconclusive on fetal RHD genotyping and 19 were falsely
predicted genotypically to be RHD negative (table 1).
The odds of correctly identifying RHD positive and RHD
negative fetuses increased significantly with gestational age,
with low levels of false negative results after 11 weeks’
gestation. Table 1 shows the summary statistics for <11, 11-13,
14-17, 18-23, and >23 weeks⇓. Figure 2⇓ shows how sensitivity
for correctly identifying RHD positive fetuses increased on a
week by week basis and how before 11 weeks, confidence
intervals were wider and sensitivities not good enough to support
routine introduction of the test.
Discussion
Previous studies have shown that mass throughput RHD
genotyping of cell-free fetal DNA is accurate if performed in
the third trimester of pregnancy.7 8 In this population based
cohort study, we evaluated accuracy across a wider range of
gestations and have shown that it is highly accurate from 11
weeks’ gestation; before this the percentage of babies falsely
predicted as RhD negative increases. For routine application of
fetalRHD genotyping, false negative results—whereby the fetus
is predicted to be RhD negative when it is really RhD
positive—pose the greatest concern as mothers will not receive
prophylactic anti-RhD immunoglobulin andmight alloimmunise,
which would put babies in subsequent pregnancies at risk of
considerable morbidity or mortality. As the sensitivity improves
with gestation, this risk can therefore be mitigated by optimal
timing of testing, by repeating cell-free fetal DNA testing in
women predicted to be carrying an RhD negative baby, or by
testing cord blood of babies predicted to be RhD negative. The
latter two interventions would, however, impact on the cost
effectiveness and applicability of a large scale programme. In
our study, the incidence of false RHD negative results before
11 weeks’ gestation was 16/865 (1.85%, 95% confidence
interval 1.14% to 2.98%). This might be because of low
concentrations of cell-free fetal DNA in early pregnancy.13After
11 weeks the incidence of false negative results was
considerably lower (at 1/956 between 11-13weeks; 0.1%, 0.02%
to 0.59%) and did not decrease between 11 and 24 weeks, in
line with recent evidence that concentrations of cell free fetal
DNA increase only minimally between 10 and 20 weeks’
gestation.14 The small number of false RHD negative results
after 11 weeks’ gestation would only minimally increase the
risk of alloimmunisation in the population, around 0.07/100 000
births (table 2⇓). This figure could well be offset by the potential
to improve overall uptake of the immunoprophylaxis programme
for RhD negative women carrying an RHD positive baby, as
counselling and follow-up could be targeted at these women to
try to improve anti-RhD immunoglobulin uptake when it is
definitively needed.
In Denmark11 and the Netherlands12 routine fetal RHD
genotyping has been introduced at 25 and 28 weeks’ gestation,
respectively, and is used to direct routine third trimester
antenatal prophylaxis with anti-RhD immunoglobulin. While
such strategies can minimise the administration of unnecessary
anti-RhD immunoglobulin in a routine immunoprophylaxis
programme, they do not take account of anti-RhD
immunoglobulin required for sensitising events earlier in
pregnancy. Earlier knowledge of fetal RHD genotype would
further reduce unnecessary administration of anti-RhD
immunoglobulin as well as potentially enhancing any financial
savings as prophylactic anti-RhD immunoglobulin and costly
estimations of fetomaternal haemorrhage by Kleihauer-Betke
test or flow cytometry could be avoided in RhD negative
mothers carrying an RHD negative baby, savings realised not
only for routine prophylaxis at 28 weeks but also for sensitising
events occurring at earlier gestations.15 16
Conclusions
Mass throughput fetal RHD genotyping is sufficiently accurate
to be used from 11 weeks’ gestation. To maximise reduction in
administration of anti-RhD immunoglobulin and to minimise
costs to both women and health services, testing should be
performed as soon as possible from 11 weeks’ gestation to
coincide with routine antenatal visits.
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What is already known on this topic
Previous studies have predominantly assessed accuracy of fetal RHD genotyping at relatively late gestations (24-30 weeks)
At this stage in pregnancy it is highly accurate and can be used to direct immunoprophylaxis to those RhD negative women carrying an
RHD positive baby and thereby reduce unnecessary exposure to anti-RhD immunoglobulin
What this study adds
Mass throughput fetal RHD genotyping is highly accurate from 11 weeks’ gestation, but before this the number of babies falsely predicted
to be RhD negative is high
To maximise benefit of routine fetal RHD genotyping and to avoid potential sensitisation by withholding anti-RhD immunoglobulin in
women falsely predicted to be carrying an RhD negative baby, testing should be done only from 11 weeks’ gestation
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Tables
Table 1| Prediction of fetal RhD status by fetal RHD genotyping of cell-free DNA in maternal plasma compared with results of cord blood
typing of RhD
Total samplesGestational age in completed weeks*
>2418-2314-1711-13<11
1920696321225341337Correct RhD negative
2563864492272535400Correct RhD positive
19011116False RhD negative
1875141False RhD positive
852419101319Inconclusive confirmed RhD
negative
3087150336292Inconclusive confirmed RhD
positive
49131662888542956865Total
99.34 (98.98 to
99.58)
100.00 (99.59 to
100.00)
99.82 (9.96 to 99.97)99.67 (98.17 to
99.94)
99.83 (99.06 to
99.97)
96.85 (94.95 to
98.05)
Sensitivity RhD positive (95%
CI)†
94.91 (93.86 to
95.78)
95.74 (94.01 to
96.98)
93.04 (89.86 to
95.28)
95.34 (91.85 to
97.38)
95.25 (92.53 to
97.01)
94.40 (91.51 to
96.34)
Specificity RhD positive (95%
CI)†
*Gestational ages shown are in completed postmenstrual weeks (for example, 11 weeks=11 weeks 0 days to 11 weeks + 6 days).
†Assuming all inconclusive results are treated as RhD positive.
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Table 2| Impact of false negative results in terms of alloimmunisation, and risk to subsequent pregnancies
Gestational age in weeks
>2418-2314-1711-13<11
0.00 (0 to 0.23)0.11 (0.02 to 0.64)0.18 (0.03 to 1.04)0.10 (0.02 to 0.59)1.85 (1.14 to 2.98)False RhD negative % (CI)
0 (0 to 20)9.9 (2 to 58)16.2 (3 to 94)9.0 (2 to 53)167 (103 to 268)Risk of alloimmunisation per 100 000
pregnancies if cord blood typing is not
performed (CI)*
0 (0 to 0.9)0.44 0.08 to 2.6)0.72 (0.1 to 4.2)0.4 (0.08 to 2.4)7.4 (4.6 to 11.9)Risk per 100 000 pregnancies of having
subsequent severely affected child if cord
blood typing is not performed*†
0 (0 to 0.1)1.1 (0.2 to 6)1.8 (0.3 to 10)1.0 (0.2 to 6)19 (11 to 30)Risk of alloimmunisation per 100 000
pregnancies if cord typing is performed in
pregnancies when cell-free fetal DNA result
is RHD negative
0 (0 to 0.11)0.05 (0.009 to 0.28)0.08 (0.01 to 0.46)0.04 (0.009 to 0.26)0.82 (0.5 to 1.3)Risk per 100 000 pregnancies of having
subsequent severely affected child if cord
blood typing is performed in pregnancies
when cell free fetal DNA result is RHD
negative*
*Assuming 9% alloimmunised if not given anti-RhD immunoglobulin at delivery (published range 4.3-9%) and 1% alloimmunised if given anti-RhD immunoglobulin
at delivery based on cord RhD type.
†Assuming 62% have subsequent baby 71.5% of which are RhD positive, risk of death for affected baby is 5%. Risk of permanent neurological damage in affected
baby is 5%.8
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Figures
Fig 1 Maternity care pathway followed in England by gestational age together with number of women tested at each
completed week of gestation. Dark bars indicate recommended gestations for tests but not all women book early in pregnancy
and some attend late for their anomaly scan, so lighter bars show extended range of gestations, when women might have
been recruited when attending for these indications
Fig 2 Sensitivity of determining RHD positive fetuses according to gestational age (inconclusive results treated as RHD
positive). Fitted model (solid line) and 95% bootstrap confidence intervals (dashed lines) obtained from generalised linear
model incorporating random intercept to take into account repeat measures from same women over pregnancy. Weekly
estimates are overlaid with point size proportional to number of women tested during each week
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